» Articles » PMID: 18931081

Epstein-Barr Virus-encoded EBNA1 Modulates the AP-1 Transcription Factor Pathway in Nasopharyngeal Carcinoma Cells and Enhances Angiogenesis in Vitro

Overview
Journal J Gen Virol
Specialty Microbiology
Date 2008 Oct 22
PMID 18931081
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

The Epstein-Barr virus (EBV)-encoded EBNA1 protein is expressed in all virus-associated tumours, including nasopharyngeal carcinoma (NPC), where it plays an essential role in EBV genome maintenance, replication and transcription. Previous studies suggest that EBNA1 may have additional effects relevant to oncogenesis, including enhancement of cell survival, raising the possibility that EBNA1 may influence cellular gene expression. We have recently demonstrated by gene expression microarray profiling in an NPC cell model that EBNA1 influences the expression of a range of cellular genes, including those involved in transcription, translation and cell signalling. Here, we report for the first time that EBNA1 enhances activity of the AP-1 transcription factor in NPC cells and demonstrate that this is achieved by EBNA1 binding to the promoters of c-Jun and ATF2, enhancing their expression. In addition, we demonstrate elevated expression of the AP-1 targets interleukin 8, vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1alpha in response to EBNA1 expression, which enhances microtubule formation in an in vitro angiogenesis assay. Furthermore, we confirm elevation of VEGF and the phosphorylated isoforms of c-Jun and ATF2 in NPC biopsies. These findings implicate EBNA1 in the angiogenic process and suggest that this viral protein might directly contribute to the development and aggressively metastatic nature of NPC.

Citing Articles

Epstein-Barr virus hijacks histone demethylase machinery to drive epithelial malignancy progression through KDM5B upregulation.

Zhou Y, Jiang J, He S, Li Y, Cheng X, Liu S Signal Transduct Target Ther. 2025; 10(1):83.

PMID: 40059116 PMC: 11891327. DOI: 10.1038/s41392-025-02163-5.


VEGF-Virus Interactions: Pathogenic Mechanisms and Therapeutic Applications.

Sanchez-Martinez C, Grueso E, Calvo-Lopez T, Martinez-Ortega J, Ruiz A, Almendral J Cells. 2024; 13(21.

PMID: 39513922 PMC: 11545703. DOI: 10.3390/cells13211815.


The plasma EBV DNA load with IL-6 and VEGF levels as predictive and prognostic biomarker in nasopharyngeal carcinoma.

Ghose S, Roy S, Ghosh V, Sharawat S, Pramanik R, Biswas S Virol J. 2024; 21(1):224.

PMID: 39304953 PMC: 11414088. DOI: 10.1186/s12985-024-02473-0.


Angiogenesis in nasopharyngeal carcinoma: insights, imaging, and therapeutic strategies.

Xia C, Zhao J, Huang Y, Miao H, Zhao F Front Oncol. 2024; 14:1331064.

PMID: 38863627 PMC: 11165036. DOI: 10.3389/fonc.2024.1331064.


Herpesvirus Infection of Endothelial Cells as a Systemic Pathological Axis in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Nunes J, Kell D, Pretorius E Viruses. 2024; 16(4).

PMID: 38675914 PMC: 11053605. DOI: 10.3390/v16040572.